CR

Carlo Rizzuto

Managing Director at Versant Ventures

New York, New York

Overview

Work Experience

VV
Versant Ventures

  • Managing Director

    2022

  • Partner

    2012 - 2022

    Director, Graphite Bio (GRPH) Director, Century Therapeutics (IPSC) Director, Jnana Therapeutics Director, FirstLight Bio Director, 858 Therapeutics Director, Stablix Director, Nested Therapeutics Director, Pandion Therapeutics (PAND, acquired) Director, Venatorx (2017-2022) Founding CEO, Kyras Therapeutics (2015-2017) Chief Business Officer, Anokion (2014-2017)

Highline Therapeutics

  • CEO

    2015 - 2022

    Highline Therapeutics is a biotech incubator established by Versant Ventures in New York City. Modeled on Blueline Bioscience in Toronto, Highline aims to identify and accelerate translational research and biotech company formation. Highline will partner with both local academic institutions and pharmaceutical companies to help bridge the gap between academic science and the development of novel therapeutics.

N
Novartis

  • Global Program Team Director

    2010 - 2012

    Lead global, cross-functional team developing intelligent medicines by integrating electronics and pharmaceuticals to enable remote patient monitoring/e-health applications

Novartis International AG

  • Assistant to the CEO

    2010 - 2010

N
Novartis

  • Assistant to CEO - Pharmaceuticals

    2009 - 2010

M&
McKinsey & Company

  • Associate Principal

    2002 - 2008

engeneOS

  • Business Development Manager

    2000 - 2002

Education

Investments

Nexo Therapeutics

Series A

Total Funding: $60M

Jnana Therapeutics

Series A

Total Funding: $160M

Nested Therapeutics

Seed

Total Funding: $35M

Stablix

Series A

Total Funding: $63M

Relevant Websites